What would you do if you already had symptoms? I already have subjective cognitive decline and my LDL is 219mg/dl, HDL37,LDL159.I am an APOE4 carrier and have an APP and a PSEN2 mutation.When I joined before all of this kicked in I just wanted to live longer. Have been trying to reverse this since I was 54 I am now 58 and am still very sick. Currently trying to lower Homocysteine and blood sugar. I can't remember where I leave anything
Aβ plaques are the initiators of the disease, which also involve tau as a secondary aspect. I'd suggest you try the following combination to dissolve these Aβ plaques and render the dissolved portion non-toxic. All items are available from Amazon in the US, but HEPPS may be a bit more difficult to get in the UK--
Alzheimer's protocol — experimental
Once a day for several months—
HEPPS [aka, EPPS] — 1g (1/4 level teaspoon)
Taurine — 8g (2 level teaspoons)
Oleuropein — 200 mg
Vitamin C — 2g
References—
Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
Aβ is upstream of tau in AD pathogenesis and triggers the conversion of tau from a normal to a toxic state, but there is also evidence that toxic tau enhances Aβ toxicity via a feedback loop. Because soluble toxic aggregates of both Aβ and tau can self-propagate and spread throughout the brain by prionlike mechanisms, successful therapeutic intervention for AD would benefit from detecting these species before plaques, tangles, and cognitive impairment become evident and from interfering with the destructive biochemical pathways that they initiate.
https://www.ncbi.nlm...pubmed/24493463
EPPS reduces Aβ-aggregate-induced memory deficits in mice
Previously, we reported a series of small ionic molecules that could accelerate the formation of Aβ aggregates in vitro. Unexpectedly, in addition to the compounds facilitating Aβ aggregation, we identified six small molecules that inhibited the formation of Aβ oligomers and fibrils13. In the current study, we tested whether these molecules could affect AD-like cognitive impairments of rodents. For this purpose, we induced memory deficits in 8.5-week-old Imprinting Control Region (ICR) mice (male, n=9–10 per group) by injecting Aβ42 aggregates (Fig. 1a,b) into the intracerebroventricular region14. This Aβ-infusion model allowed us to control the onset of abnormal Aβ deposition before or after the administration of our compounds. Among the six orally administered molecules, only 4-(2-hydroxyethyl)-1-piperazinepropanesulphonic acid (EPPS) ameliorated AD-like phenotypes in our mouse model.
https://www.nature.com/articles/ncomms9997
Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease
We orally administered taurine via drinking water to adult APP/PS1 transgenic mouse model for 6 weeks. Taurine treatment rescued cognitive deficits in APP/PS1 mice up to the age-matching wild-type mice in Y-maze and passive avoidance tests without modifying the behaviours of cognitively normal mice.
https://www.nature.com/articles/srep07467
Noncovalent Interaction Between Amyloid-β-Peptide (1-40) and Oleuropein Studied by Electrospray Ionization Mass Spectrometry
The successful detection of the noncovalent complex between Aβ and OE [Oleuropein] could be invaluable in a series of studies focused on screening the ability of several bioactive phytochemicals in terms of complexating Aβ and Aβox and “locking” them in a non-toxic conformation, thus acting as potential anti-amyloidogenic agents. This may offer an ideal protective alternative against Aβ toxicity.
http://www.sciencedirect.com/science/article/pii/S104403050501024X?via%3Dihub
Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases.
Ascorbic acid acts mainly by decreasing oxidative stress and reducing the formation of protein aggregates, which may contribute to the reduction of cognitive and/or motor impairments observed in neurodegenerative processes.
https://www.ncbi.nlm.nih.gov/pubmed/28980404
Edited by Turnbuckle, 11 January 2018 - 07:43 PM.